Treatment of human cells derived from MERRF syndrome by peptide-mediated mitochondrial delivery.

@article{Chang2013TreatmentOH,
  title={Treatment of human cells derived from MERRF syndrome by peptide-mediated mitochondrial delivery.},
  author={Jui-Chih Chang and Ko-Hung Liu and C Chuang and H M Su and Yau-Huei Wei and S E Kuo and Chin San Liu},
  journal={Cytotherapy},
  year={2013},
  volume={15 12},
  pages={1580-96}
}
BACKGROUND AIMS The feasibility of delivering mitochondria using the cell-penetrating peptide Pep-1 for the treatment of MERRF (myoclonic epilepsy with ragged red fibers) syndrome, which is caused by point mutations in the transfer RNA genes of mitochondrial DNA, is examined further using cellular models derived from patients with MERRF syndrome. METHODS Homogenesis of mitochondria (wild-type mitochondria) isolated from normal donor cells with about 83.5% preserved activity were delivered… CONTINUE READING